Le Lézard
Classified in: Health
Subject: SVY

The global HPAPIs market is expected to reach USD 26.84 billion by 2023 from USD 17.72 billion in 2018, at a CAGR 8.7%


LONDON, April 26, 2018 /PRNewswire/ -- The global HPAPIs market projected to grow at a CAGR of 8.7%
The global HPAPIs market is expected to reach USD 26.84 billion by 2023 from USD 17.72 billion in 2018, at a CAGR 8.7%. The growth in this market is driven by factors such as increasing demand for oncology drugs, growing demand for antibody-drug conjugates, increasing focus of leading pharmaceutical companies on HPAPIs, advancements in HPAPI manufacturing technologies, and growing focus on precision medicine. On the other hand, the requirement of large investments, discrepancies in HPAPI banding systems, uncertainties associated with products, and the high risk of cross-contamination are expected to limit market growth in the coming years. The need for appropriate process designs and the constant evolution of industry standards and technologies are also expected to challenge market growth to a certain extent.

Download the full report: https://www.reportbuyer.com/product/5073744

The generic HPAPIs segment is expected to grow at the highest CAGR during the forecast period
Based on type, the HPAPIs market is segmented into innovative and generic APIs.The generic HPAPIs segment is expected to register the highest growth rate during the forecast period.

The impending patent cliff, increasing healthcare costs, and government initiatives to encourage the adoption of generics are the major factors driving the growth of this market segment.

The captive manufacturers segment is expected to dominate the market in 2018
On the basis of type of manufacturer, the HPAPIs market is segmented into captive HPAPI and merchant HPAPI manufacturers.In 2018, the captive HPAPI manufacturers segment is expected to account for the largest share of the market.

The large share of this segment is attributed to the preference of innovative companies to maintain in-house manufacturing facilities for economic benefits.

Asia to witness the highest growth during the forecast period
In 2018, North America is expected to account for the largest share of the market followed by Europe. However, Asia is expected to grow at the highest CAGR of 11.8% during the forecast period. Factors such as growth in geriatric population, high prevalence of chronic and lifestyle diseases, increase in disposable income, prevalence of lifestyle- and age-related diseases, government efforts to reform healthcare and encourage the adoption of generics, and growing market for merchant manufacturers in this region owing to the low labor and manufacturing costs are driving the growth of the HPAPIs market in Asia.

The primary interviews conducted for this report can be categorized as follows:
? By Company Type: Tier 1 ? 31%; Tier 2 - 49%; Tier 3 - 20%
? By Designation: C-level- 28%; D-level- 19%; Others- 53%
? By Region: North America-31%; Europe-33%; Asia Pacific-19%; Rest of the World-17%

List of companies profiled in the report
? Pfizer (US)
? Novartis International AG (Switzerland)
? Sanofi (France)
? F. Hoffmann-La Roche (Switzerland)
? Bristol-Myers Squibb (US)
? Boehringer Ingelheim (Germany)
? Teva Pharmaceutical Industries Ltd. (Israel)
? Eli Lilly and Company (US)
? Merck (US)
? AbbVie (US)
? Mylan (US)
? Bayer (Germany)

Research Coverage:
The report provides an overview of the HPAPIs market.It aims at estimating the market size and future growth potential of this market across different segments such type, type of manufacturer, type of synthesis, therapeutic application, and region.

Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help the market leaders/new entrants in this market by providing them with the closest approximations of revenues for the overall HPAPIs market and its subsegments.This report will help stakeholders to understand the competitive landscape better and gain insights to position their businesses and help companies make suitable go-to-market strategies.

The report also will also help stakeholders understand the pulse of the market and provide them with information regarding key market drivers and opportunities.

Download the full report: https://www.reportbuyer.com/product/5073744

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +1 (718) 213 4904
Website: www.reportbuyer.com

SOURCE ReportBuyer


These press releases may also interest you

at 06:15
The "Molecular Diagnostics for Cancer: Markets Forecasts by Cancer Type, Product, and Place with Executive & Consultant Guides and Customization. 2023 to 2027" report has been added to  ResearchAndMarkets.com's offering. Exciting technical...

at 06:10
Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs), announced today that it has been awarded a EUR 1.6 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The 2-year grant...

at 06:08
Aesthetic Management Partners LLC, a manufacturer of skin-based solutions and a provider of energy-based devices announces its collaboration with Croma (Croma-Pharma® GmbH), a global player in the minimally invasive aesthetics market and a leading...

at 06:05
The 2023 U.S. soybean field trials conducted by Texas Crop Science (TCS) demonstrated an average yield increase of 21% in soybean lines incorporating the TCS yield trait. This breakthrough in performance would generate approximately $121 per acre in...

at 06:05
3EO Health, a "Point of Life" diagnostics company focused on the development of high-performing low-cost molecular diagnostics, is excited to announce the next step in their quest to make molecular testing affordable. Today, the company has published...

at 06:05
Zura Bio Limited ("Zura Bio") a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2023 financial results and recent business highlights. The Company has also...



News published on and distributed by: